Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by González Tomás Bernardo GalvánfiledCriticalGonzález Tomás Bernardo Galván
Priority to CL2015002209ApriorityCriticalpatent/CL2015002209A1/en
Publication of CL2015002209A1publicationCriticalpatent/CL2015002209A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
COMPOSICION FARMACEUTICA ORAL QUE COMPRENDE A. AL MENOS UN AGENTE ANTISEPTICO, B. UN ACEITE ESENCIAL, C. UN AGENTE ANTISEPTICO FENOLICO, D. UN AGENTE CON PROPIEDADES ANTIINFLAMATORIAS SELECCIONADO DE ALCANFOR Y E. EXCIPIENTES, PARA SU USO EN EL TRATAMIENTO Y/O LA PREVENCION DE MUCOSITIS ORAL O ESTOMATITIS PARTICULARMENTE ASOCIADA A TERAPIAS ANTICANCERIGENAS.ORAL PHARMACEUTICAL COMPOSITION THAT INCLUDES A. AT LEAST AN ANTISEPTIC AGENT, B. AN ESSENTIAL OIL, C. A PHENOLIC ANTISEPTIC AGENT, D. AN AGENT WITH SELECTED ANTI-INFLAMMATORY PROPERTIES OF REACH AND E. EXCIPIENTS, FOR USE IN THE TREATMENT AND / OR THE PREVENTION OF ORAL MUCOSITIS OR STOMATITIS PARTICULARLY ASSOCIATED WITH ANTI-BANERY THERAPIES.
CL2015002209A2015-08-072015-08-07
Oral antiseptic composition for treatment of oral mucositis.
CL2015002209A1
(en)
Use of a masp-2 inhibitor that inhibits the activation of the masp-2-dependent complement, to treat a subject suffering from catastrophic antiphospholipid syndrome (safc). (divisional application 201600908)
the use of separate sgc stimulants, scg activators and combinations with pde5 inhibitors for the treatment of multiple sclerosis (ssc) concurrent digital (du) ulcers